Variant · Other
KRAS Wildtype
CI-VAR-00004732Explore in graph →CIViC 3200
Curated evidence
Evidence by cancer (10 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 21641636
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Colorectal Adenocarcinoma1 | ||||||||
| KRAS Wildtype | Cetuximab + ChemotherapyCombination | Predictive | B | Does Not Support Sensitivity Response | 3 | submitted | EID11057The Medical Research Council (MRC) COIN trial consisted of patients with histologically confirmed adenocarcinoma of the colon or rectum, inoperable metastatic or locoregional measurable disease, and w… (full text at CIViC) PMID 21641636 · Maughan et al., 2011 · Open in CIViC | civic |
| Lung Non-Small Cell Carcinoma1 | ||||||||
| KRAS Wildtype | Cetuximab | Predictive | B | Does Not Support Sensitivity Response | 3 | submitted | EID11659In a clinical study of 49 patients, 10 patients with Non-Small Cell Lung Cancer (NSCLC) and wild-type KRAS gene were treated with Cetuximab. After 16 weeks, no clinical activity was observed. A PFS of… | |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available